Literature DB >> 15803235

Midterm follow-up study of laparoscopic dissection of uterine vessels for surgical treatment of symptomatic fibroids.

Z Holub1, A Jabor, J Lukac, L Kliment, S Urbanek.   

Abstract

BACKGROUND: This study aimed to assess laparoscopic dissection of uterine vessels (LDUV) for symptomatic fibroids in women.
METHODS: A total of 69 women entered the study between March 2000 and June 2003. In this case series, 68 consecutive women underwent LDUV using ultrasonically activated sheers or electrosurgery for the treatment of fibroids over 3 years (median follow-up period, 14.5 months). Ultrasound or magnetic resonance imaging was carried out 3, 6, 12, 24, and 36 months after treatment. The tissue markers, gonadotropin, and estrogen levels were studied postoperatively.
RESULTS: Almost all the patients (98.5%) had a successful LDUV with a low rate (7.3%) of postoperative complications. The time of surgery ranged from 15 to 50 min (mean, 30.8 min). The blood loss was minimal (mean, 14.7 ml), and the hospital stay was 2.4 days. Symptom improvement (menorrhagia or dysmenorrhoea) was 93.2%, and the average reduction in the dominant myoma was 57.8% during a follow-up period longer than 12 months. All the patients with anemia had normal red cell counts after 3 months.
CONCLUSIONS: Uterine volume and the dominant fibroid were significantly reduced and symptoms were improved by LDUV. The laparoscopic procedure is associated with insignificant tissue damage and normal gonadotropin and estrogen levels.

Entities:  

Mesh:

Year:  2004        PMID: 15803235     DOI: 10.1007/s00464-003-9245-z

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  19 in total

1.  Massive vault necrosis with bladder fistula after uterine artery embolisation.

Authors:  Amr H El-Shalakany; Mohammad H Nasr El-Din; Gamal A Wafa; Mohammad E Azzam; Ahmad El-Dorry
Journal:  BJOG       Date:  2003-02       Impact factor: 6.531

2.  Laparoscopic bipolar coagulation of uterine vessels to treat symptomatic leiomyomas.

Authors:  W M Liu
Journal:  J Am Assoc Gynecol Laparosc       Date:  2000-02

3.  Estimation of nongravid uterine volume based on a nomogram of gravid uterine volume: its value in gynecologic uterine abnormalities.

Authors:  S R Goldstein; S C Horii; J R Snyder; B N Raghavendra; B Subramanyam
Journal:  Obstet Gynecol       Date:  1988-07       Impact factor: 7.661

4.  Uterine artery embolization in the primary treatment of uterine leiomyomas: technical features and prospective follow-up with clinical and sonographic examinations in 58 patients.

Authors:  L Brunereau; D Herbreteau; S Gallas; J P Cottier; J L Lebrun; F Tranquart; F Fauchier; G Body; P Rouleau
Journal:  AJR Am J Roentgenol       Date:  2000-11       Impact factor: 3.959

5.  Ovarian failure after uterine artery embolization for treatment of myomas.

Authors:  N H Stringer; T Grant; J Park; L Oldham
Journal:  J Am Assoc Gynecol Laparosc       Date:  2000-08

6.  Laparoscopic uterine artery occlusion for symptomatic leiomyomas.

Authors:  Moises Lichtinger; Laurey Hallson; Patricia Calvo; Ghea Adeboyejo
Journal:  J Am Assoc Gynecol Laparosc       Date:  2002-05

7.  Laparoscopic bipolar coagulation of uterine vessels to treat symptomatic myomas in women with elevated Ca 125.

Authors:  Y K Yen; W M Liu; C C Yuan; H T Ng
Journal:  J Am Assoc Gynecol Laparosc       Date:  2001-05

8.  Laparoscopic bipolar coagulation of uterine vessels: a new method for treating symptomatic fibroids.

Authors:  W M Liu; H T Ng; Y C Wu; Y K Yen; C C Yuan
Journal:  Fertil Steril       Date:  2001-02       Impact factor: 7.329

9.  Short-term results from laparoscopic dissection of uterine vessels in women with symptomatic fibroids.

Authors:  Z Holub; J Lukác; L Kliment; S Urbánek
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2003-09-10       Impact factor: 2.435

Review 10.  Changing trends in treatment of leiomyomata uteri.

Authors:  B S Verkauf
Journal:  Curr Opin Obstet Gynecol       Date:  1993-06       Impact factor: 1.927

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.